- Addiction Medicine
- Allergy/ Immunology
- Cardiovascular Disease
- Emergency Medicine
- Family Medicine
- Infectious Disease
- Internal Medicine
- Medical Oncology
- Obstetrics and Gynaecology
- Otorhinolaryngology or ENT (ear, nose and throat)
- Palliative Care
- Physical Therapy
- Sport Medicine
- Travel Medicine
By Dr. Alissa Wright on January 25, 2017
Canadians travel a lot and are increasingly traveling to more exotic and remote destinations. Unfortunately, travel does carry certain risks with respect to infection. Post-travel assessment of a febrile patient must be comprehensive, but completed in a timely manner so that patients get the care they need.
By Dr. Soren Gantt on June 8, 2016
Approximately 1 out of every 150 live-born infants has congenital CMV infection (cCMV). Of these, most are asymptomatic. However, more than 20% will suffer permanent neurologic sequelae, including hearing loss, intellectual disability, and visual deficits. In fact, cCMV is responsible for 25% of all childhood hearing loss, and is the second most common cause of intellectual disability after Down syndrome.
By Dr. Natasha Press on March 5, 2014
The most recent AHA guidelines (2007) have limited antibiotic prophylaxis to those patients at highest-risk for developing endocarditis and who are undergoing high-risk invasive procedures.
By Dr. Sarah Stone on October 7, 2013
As a family physician practicing at St Paul’s Immunodeficiency clinic in Vancouver, I have cared for patients living with HIV for over 10 years. Many patients are referred to the clinic at a stage of disease where treatment would have been beneficial if started earlier.
By Dr. Jan Hajek on February 18, 2013
The world is increasingly connected and infectious diseases know no borders. We need to be pro-active in adequately screening our patients.
By Dr. Eric Yoshida on July 18, 2011
This year, based on the phase III studies published in the New England Journal of Medicine, the FDA approved the new protease inhibitors, telapravir and boceprevir in combination with pegIFN and ribavirin for patients with HCV G1 infections.
By Dr. Ted Steiner on July 4, 2011
Based on recent literature, my current practice is to carefully consider whether PPIs or H2 blockers are truly indicated in inpatients, and to stop them if they are not.
By Dr. Julio Montaner on November 29, 2010
Remarkable advances in HIV/AIDS treatment have been achieved over the past two decades. Most significant among these advances is the development of highly active antiretroviral therapy, a combination of antiretroviral drugs that suppress HIV replication.
By Dr. Natasha Press on April 16, 2010
A 32 year old woman, otherwise healthy, presented with a “spider-bite”. On exam, she had a tender abscess on her buttock. It was associated with some surrounding cellulitis but no fever or other systemic features.